[Replacement Page 25]{.underline}

Table 6. Demographic and Baseline Disease Characteristics: Studies 437
and 438

+-----------------------+--------+-------------+--------+-------------+
|                       | *      |             | *      |             |
|                       | *Study |             | *Study |             |
|                       | GS‑9   |             | GS‑9   |             |
|                       | 8‑437\ |             | 8‑438\ |             |
|                       | HBeAg+ |             | H      |             |
|                       | C      |             | BeAg-/ |             |
|                       | hronic |             | anti-H |             |
|                       | HBV    |             | Be/HBV |             |
|                       | Infec  |             | DNA    |             |
|                       | tion** |             | HBV    |             |
|                       |        |             | Infec  |             |
|                       |        |             | tion** |             |
+-----------------------+--------+-------------+--------+-------------+
|                       | **\    | **Adefovir  | **\    | **Adefovir  |
|                       | Pl     | Dipivoxil\  | Pl     | Dipivoxil\  |
|                       | acebo\ | 10 mg\      | acebo\ | 10 mg\      |
|                       | N =    | N = 171**   | N      | N = 123**   |
|                       |  167** |             | = 61** |             |
+-----------------------+--------+-------------+--------+-------------+
| Age (years)           |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 35     | 32          | 45     | 46          |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 28 to  | 25 to 42    | 39 to  | 40 to 53    |
|                       | 43     |             | 53     |             |
+-----------------------+--------+-------------+--------+-------------+
| Gender                |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Males               | 119    | 130 (76%)   | 50     | 102 (83%)   |
|                       | (71%)  |             | (82%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| > Females             | 48     | 41 (24%)    | 11     | 21 (17%)    |
|                       | (29%)  |             | (18%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| Race                  |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Caucasian           | 60     | 60 (35%)    | 40     | 82 (67%)    |
|                       | (36%)  |             | (66%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| > Black               | 3 (2%) | 8 (5%)      | 1 (2%) | 5 (4%)      |
+-----------------------+--------+-------------+--------+-------------+
| > Asian               | 101    | 102 (60%)   | 20     | 36 (29%)    |
|                       | (60%)  |             | (33%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| > Other               | 3 (2%) | 1 (\< 1 %)  | 0%     | 0%          |
+-----------------------+--------+-------------+--------+-------------+
| Prior HBV Therapy \*  |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Interferon-         | 35     | 42 (25%)    | 28     | 48 (39%)    |
|                       | (21%)  |             | (46%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| > Lamivudine          | 3 (2%) | 1 (1%)      | 4 (7%) | 10 (8%)     |
+-----------------------+--------+-------------+--------+-------------+
| > Other               | 15     | 17 (10%)    | 7      | 7 (6%)      |
|                       | (9%)   |             | (11%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| Total Knodell HAI     |        |             |        |             |
| Score                 |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 10     | 9.5         | 9      | 10          |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 8 to   | 8 to 11     | 6 to   | 8 to 12     |
|                       | 12     |             | 11     |             |
+-----------------------+--------+-------------+--------+-------------+
| Knodell               |        |             |        |             |
| Necro-inflammatory    |        |             |        |             |
| Score                 |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 8      | 7           | 7      | 8           |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 7 to   | 7 to 9      | 5 to   | 7 to 10     |
|                       | 10     |             | 10     |             |
+-----------------------+--------+-------------+--------+-------------+
| Knodell Fibrosis      |        |             |        |             |
| Score                 |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 1      | 1           | 1      | 1           |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 1 to 3 | 1 to 3      | 1 to 3 | 1 to 3      |
+-----------------------+--------+-------------+--------+-------------+
| Cirrhosis             | 13     | 12 (7%)     | 6      | 14 (11%)    |
|                       | (8%)   |             | (10%)  |             |
+-----------------------+--------+-------------+--------+-------------+
| HBV-DNA (log~10~      |        |             |        |             |
| copies/mL)            |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 8.33   | 8.40        | 7.05   | 7.10        |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 7.5 to | 7.69 to     | 6.24   | 6.35 to     |
|                       | 8.76   | 8.87        | to     | 7.53        |
|                       |        |             | 7.67   |             |
+-----------------------+--------+-------------+--------+-------------+
| ALT (IU/L)            |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 94     | 95          | 100    | 93          |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 69     | 65 to 165   | 72 to  | 69 to 165   |
|                       | to159  |             | 161    |             |
+-----------------------+--------+-------------+--------+-------------+
| ALT ( x ULN)          |        |             |        |             |
+-----------------------+--------+-------------+--------+-------------+
| > Median              | 2.4    | 2.3         | 2.4    | 2.3         |
+-----------------------+--------+-------------+--------+-------------+
| > Q1 to Q3            | 1.7 to | 1.6 to 3.9  | 1.7 to | 1.7 to 3.8  |
|                       | 3.9    |             | 3.9    |             |
+-----------------------+--------+-------------+--------+-------------+

\* Prior HBV‑medications for the purpose of this analysis was classed as
interferon alpha only as the number of patients taking other prior
medications was low per protocol exclusion criteria.

Source: GS‑98‑437 ICSR, Table 11‑2, 11‑3, 11‑4; GS‑98‑438 ICSR, Table
11‑2, 11‑3